 Home > Medical News > Latest Medical News > Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China

Hutchison Medical's introduction of anti-tumor drug tazemetostat tablets for more than 300 million US dollars applies for clinical application in China

 Last Update: 2021-12-30
 Source: Internet
 Author: User

Tags

crispr clinical trial

colace drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 8, the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China showed that a clinical trial application for tazemetostat hydrobromide tablets jointly submitted by Hutchison Medicine and Epizyme was accepted

Screenshot source: CDE official website

Public information shows that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.

As an EZH2 inhibitor, tazemetostat can inhibit the methylation of histone H3 lysine 27 by inhibiting EZH2, restore the expression of tumor suppressor genes, allow B cells to continue to differentiate or produce apoptosis, thereby controlling tumor growth

Prior to this (August this year), Hutchison Medicine and Epizyme reached a cooperation and obtained the development and commercialization rights of tazemetostat in Greater China (including Mainland China, Hong Kong, Macau and Taiwan)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.